Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.65 and traded as low as $0.38. Eagle Pharmaceuticals shares last traded at $0.38, with a volume of 9,312 shares changing hands.
Eagle Pharmaceuticals Trading Up 11.8%
The business’s 50-day simple moving average is $0.65 and its 200-day simple moving average is $2.10. The company has a market capitalization of $4.94 million, a PE ratio of 0.32 and a beta of 0.83.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
See Also
- Five stocks we like better than Eagle Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- First Time Since 2007: All Warnings Active
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
